NCT00811850

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution	1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
DRUG	fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution	1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2008-12-19
• Last updated: 2019-04-24
• Results posted: 2012-08-01

Locations

1 site across 1 country: United States